Educational | Labcorp Women's Health

May 29, 2026

Identifying familial cardiac risk earlier in clinical practice

Explore comprehensive information on hereditary heart disease and how genetic testing helps identify risks, enabling prevention and treatment strategies.

May 22, 2026

From wellness to warning: Identifying familial cardiac risks early

Inherited cardiac conditions such as familial hypercholesterolemia, arrhythmias, and cardiomyopathies often go unrecognized in primary care settings until patients reach your practice with advanced disease.

April 6, 2026

Gaps in CFTR Carrier Screening: Population Diversity and Variant Representation

April 6, 2026

The Role of Deletion and Duplication Analysis in Cystic Fibrosis Carrier Screening

February 13, 2024

Optical genome mapping innovation

Watch as our senior director of clinical cytogenetics explores how advances in chromosome biology are shaping clinical molecular cytogenetic testing. He also explains how optical genome mapping may provide additional clinical insight.

November 30, 2025

Preventative intervention uptake among women with pathogenic germline variants in breast cancer risk genes

Sarah M. Young (Nielsen), MS; Emily M. Russell, PhD; Heidi Chwan Ko, DO; Rebecca A. Previs, MD, MS; Rachel E. Ellsworth, PhD;
Daniel Pineda-Alvarez, MD; Edward D. Esplin, MD, PhD; Kevin Hughes, MD; Stacy W. Gray, MD; Nadine M. Tung, MD; Allison W. Kurian, MD, MSc

Event: NSGC 2025

November 30, 2025

Referral indications for which whole exome or genome sequencing is offered by genetic counselors in a prenatal setting in 2024

Rachel Lanning, MS, CGC; Lauren Petrarca, MS, CGC

Event: NSGC 2025

November 30, 2025

Homozygous variants excluding the p.Phe508del are prevalent among patients with cystic fibrosis, particularly in those with non-white self-reported

Daniel E. Pineda-Alvarez, Karen Ouyang, Tali Ekstein, Vivian Weinblatt, Dana Neitzel, John Garcia

Event: NSGC 2025

November 30, 2025

Evaluating Pre-Test Clinical Patterns via CPT Code Enrichment in CFTR 5T11TG Compound Heterozygotes

Tali Ekstein, John Garcia, Dana Neitzel, Vivian Weinblatt, Karen Ouyang, Daniel E. Pineda-Alvarez

Event: NSGC 2025

November 30, 2025

Factors influencing uptake of carrier screening panels in the prenatal setting

Elizabeth Francisco, MS, CGC; Jaime Follmer Blanchard, MS, CGC; Adee Pintzov, MS, CGC; Lindsey Victoria, MSPH, CGC; Kathlyn Hanauer, MS, CGC

Event: NSGC 2025

Subscribe to Educational

Managing Your Health

Diseases & Therapeutic Areas

Treatment Modalities & Methods

Scientific Lab Disciplines

Labs

Industries

Search Diagnostic Test Menu

Identifying familial cardiac risk earlier in clinical practice

From wellness to warning: Identifying familial cardiac risks early

Gaps in CFTR Carrier Screening: Population Diversity and Variant Representation

The Role of Deletion and Duplication Analysis in Cystic Fibrosis Carrier Screening

Optical genome mapping innovation

Preventative intervention uptake among women with pathogenic germline variants in breast cancer risk genes

Referral indications for which whole exome or genome sequencing is offered by genetic counselors in a prenatal setting in 2024

Homozygous variants excluding the p.Phe508del are prevalent among patients with cystic fibrosis, particularly in those with non-white self-reported

Evaluating Pre-Test Clinical Patterns via CPT Code Enrichment in CFTR 5T11TG Compound Heterozygotes

Factors influencing uptake of carrier screening panels in the prenatal setting